Comparing Risk in Synthetic vs Immune-based Discovery: Why Synthetic VHH Antibodies are the Future of Antibody Discovery The biotech and pharma industies thrive on a balance of caution and innovation, carefully managing risks, while pushing the boundaries. In VHH...
Anti-LRP6 VHHs: Precision Targeting of the Wnt Pathway for Cancer Therapy Decoding Wnt Signalling Challenges in Cancer Therapy The Wnt signalling pathway is a critical player in cancer progression, implicated in tumour growth, resistance mechanisms, and...
Solid Tumour Targeting – VHH antibodies as building blocks for advanced cancer therapies Cancer continues to pose a significant challenge in the realm of biomedical research, particularly with respect to solid tumors, which constitute over 90% of adult cancer...
Unlocking Affordable Biologics: VHH Antibodies in Baker’s Yeast The production of traditional IgG monoclonal antibodies has long been hindered by their complexity. These molecules require complex and costly manufacturing processes, with estimated production costs...
From monoclonals to bi-specifics: Harnessing the transformative power of VHHs to supercharge IgG therapeutics Updated on Feb. 16th, 2025 – Since their discovery over thirty years ago, monoclonal antibodies (mAbs) based on Immunoglobulin G (IgG) have...
Challenging assumptions in antigen QC for antibody discovery success Not all projects go as planned, but breakthroughs often emerge from the most unexpected challenges. This case study explores how a technical obstacle during early QC could have derailed a VHH...
